A Dual-Fusogenic Virus-like Vector Enables Direct Cytosolic Delivery of mRNA Vaccines to Dendritic Cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41549530.
- Also identified by DOI 10.1021/acsnano.5c16068.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Messenger RNA (mRNA) vaccines hold significant potential for disease prevention and treatment; however, their effectiveness is limited by the inefficiency of current carriers in targeting dendritic cells (DCs) and facilitating endosomal escape to deliver mRNA into the cytosol. In this study, we develop a dual-fusogenic virus-like particle (VLP) cofunctionalized with a DC-targeting fusogen (DC-F) and an endosomal fusogen (E-F), termed DC/E-FVLP. We show that mRNA-loaded DC/E-FVLP<sub>mRNA</sub> selectively targets DCs and promotes fusion with both the plasma and endosomal membranes, achieving a 28.2% mRNA cytosolic delivery efficiency, which is approximately 60 times greater than that of lipid nanoparticles (LNP). Subcutaneous injection of DC/E-FVLP<sub>mRNA</sub> markedly enhances mRNA delivery to DCs in lymph nodes, resulting in improved antigen expression and presentation. At a dose of 50 ng mRNA per mouse, DC/E-FVLP<sub>mRNA</sub> efficiently induces both cellular and humoral immune responses against SARS-CoV-2 antigens and solid tumors. Thus, DC/E-FVLP<sub>mRNA</sub> holds promise as a potent mRNA vaccine delivery vehicle.
Medical subject headings
- Dendritic Cells
- Cytosol
- RNA, Messenger
- mRNA Vaccines
- COVID-19 Vaccines